BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33961340)

  • 1. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S; Velado K; Vigersky RA; Cordero TL
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
    Silva JD; Lepore G; Battelino T; Arrieta A; Castañeda J; Grossman B; Shin J; Cohen O
    Diabetes Technol Ther; 2022 Feb; 24(2):113-119. PubMed ID: 34524003
    [No Abstract]   [Full Text] [Related]  

  • 4. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
    Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
    Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
    Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
    Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
    Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.
    Elbarbary NS; Ismail EAR
    Diabetol Metab Syndr; 2023 Oct; 15(1):205. PubMed ID: 37845757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
    Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
    [No Abstract]   [Full Text] [Related]  

  • 10. Fast-Acting Insulin Aspart Use with the MiniMed
    Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [No Abstract]   [Full Text] [Related]  

  • 11. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence.
    Choudhary P; Arrieta A; van den Heuvel T; Castañeda J; Smaniotto V; Cohen O
    Diabetes Technol Ther; 2024 Mar; 26(S3):32-37. PubMed ID: 38377326
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
    Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
    Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
    Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C
    Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
    Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
    Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.
    Duffus SH; Ta'ani ZA; Slaughter JC; Niswender KD; Gregory JM
    Diabetes Obes Metab; 2020 Apr; 22(4):688-693. PubMed ID: 31709736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G.
    Jeyaventhan R; Gallen G; Choudhary P; Hussain S
    Diabetes Obes Metab; 2021 Aug; 23(8):1989-1994. PubMed ID: 33999488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.
    Kesavadev J; Basanth A; Krishnan G; Shankar A; Sanal G; Jothydev S
    Diabetes Ther; 2023 Aug; 14(8):1319-1330. PubMed ID: 37278948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.
    Akturk HK; Giordano D; Champakanath A; Brackett S; Garg S; Snell-Bergeon J
    Diabetes Obes Metab; 2020 Apr; 22(4):583-589. PubMed ID: 31789447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.